Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
N-Acetylcysteine is an Effective Adjunct Therapy for Schizophrenia
Key clinical point: N-acetylcysteine can be a useful adjunct to antipsychotics for the treatment of schizophrenia.
Major finding: Adjunctive treatment with N-acetylcysteine significantly improved negative and total Positive and Negative Syndrome Scale scores in schizophrenia after 24 weeks compared with placebo.
Study details: A meta-analysis of 7 randomized controlled trials that included 440 patients with schizophrenia (220 receiving N-acetylcysteine and 220 receiving placebo).
Disclosures: The study was supported by the National Health and Medical Research Council Project Grant. The authors declared no conflicts of interest.
Yolland COB et al. Aust N Z J Psychiatry. 2019 Dec 11. doi: 10.1177/0004867419893439.